Guardant Health (NASDAQ:GH) Stock Price Down 5.2% – Time to Sell?

Guardant Health, Inc. (NASDAQ:GH) fell 5.2% on Monday . The company traded as low as $42.58 and last traded at $42.14. 202,277 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 2,456,948 shares. The stock had previously closed at $44.47.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. lifted their price objective on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Sanford C. Bernstein reduced their price target on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Guggenheim restated a “buy” rating on shares of Guardant Health in a report on Wednesday, January 22nd. Barclays initiated coverage on shares of Guardant Health in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 target price for the company. Finally, Leerink Partners dropped their price target on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Sixteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $42.63.

Guardant Health Trading Down 1.8 %

The business has a fifty day moving average price of $38.45 and a 200 day moving average price of $30.81.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now owns 2,676 shares of the company’s stock, valued at $93,660. This represents a 46.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 2,652 shares of company stock valued at $93,192 in the last ninety days. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Guardant Health

Several institutional investors have recently modified their holdings of GH. Vanguard Group Inc. raised its stake in shares of Guardant Health by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company’s stock valued at $368,205,000 after purchasing an additional 350,606 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Guardant Health by 188.6% during the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock worth $232,325,000 after acquiring an additional 6,618,785 shares during the period. Eventide Asset Management LLC boosted its position in shares of Guardant Health by 2.0% during the 3rd quarter. Eventide Asset Management LLC now owns 3,837,300 shares of the company’s stock valued at $88,028,000 after acquiring an additional 76,762 shares in the last quarter. Geode Capital Management LLC increased its stake in Guardant Health by 1.1% in the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after acquiring an additional 29,686 shares during the period. Finally, ARK Investment Management LLC raised its position in Guardant Health by 233.5% in the third quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company’s stock worth $34,701,000 after purchasing an additional 1,059,104 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.